Interestingly, treatment of AsPC-1 xenografted mice with embelin resulted in up-regulation of death receptor DR4 and DR5, suggesting the combination of embelin with TRAIL agonists could be a viable strategy to treat human pancreatic cancer. The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.